# Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Canonical URL: https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-3625d3e2
Ticker: AKBA
Company: Akebia Therapeutics
Source: Akebia Therapeutics
Published: 2026-02-04 13:00 EST
## Summary

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the...

## Article Body
Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST.

A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.

The Emerging Outlook: Biotech Summit hosted by Guggenheim Securities, LLC, will take place February 11-12, in New York City.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com , which does not form a part of this release.

Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com
## Recent Company News
- 2026-07-02 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc8c2359) — Source: Akebia Therapeutics
- 2026-06-30 12:00 EST — [U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA](https://biopharmsignal.com/news/AKBA/u-s-renal-care-and-akebia-announce-interim-analysis-of-voice-trial-demonstrated--7cc9c9bc) — Source: Akebia Therapeutics
- 2026-06-10 12:00 EST — [Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-strengthens-vafseo-vadadustat-patent-portfolio-17cb62c9) — Source: Akebia Therapeutics
- 2026-06-01 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eb3ccebf) — Source: Akebia Therapeutics
- 2026-05-28 12:00 EST — [Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-conferenc-a2e97fe3) — Source: Akebia Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)